The arrival of Irzepatide in the UK is creating considerable interest, particularly amongst get more info individuals seeking new methods to weight control. Although still relatively recent to the UK market, Irzepatide – a dual GIP and GLP-1 receptor agonist – is showing potential in supporting patients reach long-term weight loss and better in